Trial · NCT07045155
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
NCT07045155, Phase 4, Recruiting, Chinese PLA General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis. Trials, record NCT07045155. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07045155
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
- NCT number
- NCT07045155
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Chinese PLA General Hospital
- Conditions
- Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease, Renal Anaemia, Renal Anemia, Chronic
- Interventions
- The rHuEPO Monotherapy Group (Control Group), The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group), The Pegmolesatide Monotherapy Group (Experimental group)
- First posted
- 2025-07-01
- Last updated
- 2025-09-12
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change in mean hemoglobin (Hb) levels from baseline at weeks 12 to 16 of treatment in the three groups. | During weeks 12 to 16 of the study treatment | Primary efficacy endpoints |
| Secondary | The proportion of participants in the three groups with mean Hb levels ≥100 g/L and ≤120 g/L at weeks 12 to 16 and weeks 20 to 24 of treatment. | During weeks 12 to 16 and weeks 20 to 24 of the study treatment | secondary efficacy endpoints |
| Secondary | The proportion of participants in the three groups with mean Hb levels ≥110 g/L and ≤130 g/L at weeks 12 to 16 and weeks 20 to 24 of treatment. | During weeks 12 to 16 and weeks 20 to 24 of the study treatment | secondary efficacy endpoints |
| Secondary | The proportion of participants in the three groups with mean Hb levels ≥100 g/L at weeks 12 to 16 and weeks 20 to 24 of treatment. | During weeks 12 to 16 and weeks 20 to 24 of the study treatment | secondary efficacy endpoints |
| Secondary | The proportion of participants in the three groups with mean Hb levels ≥110 g/L at weeks 12 and 24 of treatment. | at weeks 12 and 24 of treatment. | secondary efficacy endpoints |
| Secondary | The median time to first reach the target Hb level (110-130 g/L) during the treatment period in the three groups. | up to 24 weeks | secondary efficacy endpoints |
| Secondary | The absolute values of hemoglobin (Hb) levels during the treatment period in the three groups. | up to 24 weeks | secondary efficacy endpoints |
| Secondary | The absolute values of changes in hemoglobin (Hb) levels from baseline during the treatment period in the three groups. | up to 24 weeks | secondary efficacy endpoints |
| Secondary | The absolute values of red blood cell (RBC) count levels during the treatment period in the three groups. | up to 24 weeks | secondary efficacy endpoints |
| Secondary | The absolute values of hematocrit levels during the treatment period in the three groups. | up to 24 weeks | secondary efficacy endpoints |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07045155
GET https://conductscience.org/api/trials/v1/NCT07045155/registered?page=2